Effective corporate governance
Celgene is proactive in ensuring that its policies and practices support strong corporate governance, transparency and accountability. The culture at Celgene is built on integrity, ethics, sound decision-making and behaviours that reflect our values and commitment to patients.
Our highly engaged and independent Board of Directors (the “Board”) takes corporate governance seriously, helping us anticipate and incorporate leading best practices into our business model.
Corporate governance principles
Celgene’s Corporate governance principles provide the framework for the governance of the company and assist the Board of Directors in exercising its responsibilities. These principles reflect the Board’s commitment to monitoring the effectiveness of policy and decision-making both at the Board and management level, with a view to maximising stockholder value over the long term.
Financial Officer Code of Ethics
Celgene’s chief executive officer, chief financial officer and all members of the Finance Department abide by our Financial Officer Code of Ethics.
Code of Business Conduct and Ethics
Celgene was founded on the principles of honesty, integrity and accountability. These important concepts have provided the framework for our Corporate Vision, Mission and Values and form the foundation of our Code of Business Conduct and Ethics.
Compliance and Ethics
Celgene’s Compliance and Ethics Programme is designed to educate and foster an atmosphere where open communication of ethics and compliance inquiries is encouraged, and to provide all employees with a reasonable understanding of how to identify and report potential violations.
Celgene’s Code of Business Conduct and Ethics outlines the key risk areas and the principles that guide our employees’ actions.
The Compliance and Ethics Hotline is available to both employees and non-employees to report any conduct or action that may appear inconsistent with Celgene policies or applicable law.
The Sustainability Committee manages and is responsible for decision-making on sustainability- related topics as well as reviewing the progress of corporate environmental initiatives, stakeholder engagement, public report distribution, and other items as deemed appropriate. The Committee members are directly appointed by the Chairman and CEO and are selected from the Corporate Services, Finance, Technical Operations, Human Resources, Celgene Global Health, Corporate Affairs, and EHS departments.
Public Policy Advocacy and Political Activity
Public policy engagement is an important and appropriate role for private sector companies. At Celgene, we believe it is essential to work with policymakers to help ensure that the policy environment is supportive of appropriate patient access to new medications. Our public policy work reflects our commitment to improving the lives of patients and advancing the course of human health through innovation and bold pursuits of science.
Celgene expects our suppliers to deliver sustainable solutions while operating at high ethical standards and adhering to fair business practices. These suppliers are part of regional, national and international supply chains that are involved in the manufacturing process for Celgene therapies. Celgene Procurement follows a Strategic Sourcing process to identify the best suppliers and works with internal teams to ensure we get the best value from our suppliers in terms of quality, cost, service and delivery.
Medicines Australia Code of Conduct
Medicines Australia administers the Code of Conduct for Australian pharmaceutical companies. It sets the standard for the ethical marketing and promotion of prescription medicines and requires the reporting of payments by companies to healthcare professionals for the provision of services and where support is provided for education.
Therapeutics Goods Administration
As part of the Department of Health, the TGA safeguards and enhances the health of the Australian community through effective and timely regulation of therapeutic goods. The TGA is responsible for ensuring that therapeutic goods available for supply in Australia are safe and fit for their intended purpose.
Therapeutics Goods Administration